Pharmaceutical Last week’s M&A news included Merck & Co’s proposed acquisition of spin-out Tilos Therapeutics to expand its immunotherapy portfolio, though the TGF-beta sector already looks quite busy. Also, Roche’s planned $4.8 billion acquisition of Spark Therapeutics hit another stumbling block with the US competition regulator. On the regulatory front, there was US Food and Drug Administration for Roche’s B-cell lymphoma drug Polivy. Additionally, Celgene revealed that filings for its multiple sclerosis candidate ozanimod have been accepted by the FDA and the European Medicines Agency. 16 June 2019